CD&R, McKesson agree $5.8bn buyout of Option Care HealthBy Martin Holloway06/10/2026 CD&R and McKesson agree an Option Care Health buyout at $32.05 a share, valuing the infusion provider at roughly $5.8bn enterprise value.
McKesson to buy Precision Medicine Group for ~$2.25bnBy Martin Holloway26/08/2026 McKesson’s Precision Medicine Group acquisition, worth ~$2.25bn, deepens its push into oncology and specialty services, filings show.
